Department of Experimental Medicine, University of Genoa, Genoa, Italy.
Department of Molecular and Translational Medicine, Brescia, Italy.
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Epub 2016 May 27.
Programmed death 1 (PD-1) is an immunologic checkpoint that limits immune responses by delivering potent inhibitory signals to T cells on interaction with specific ligands expressed on tumor/virus-infected cells, thus contributing to immune escape mechanisms. Therapeutic PD-1 blockade has been shown to mediate tumor eradication with impressive clinical results. Little is known about the expression/function of PD-1 on human natural killer (NK) cells.
We sought to clarify whether human NK cells can express PD-1 and analyze their phenotypic/functional features.
We performed multiparametric cytofluorimetric analysis of PD-1 NK cells and their functional characterization using degranulation, cytokine production, and proliferation assays.
We provide unequivocal evidence that PD-1 is highly expressed (PD-1) on an NK cell subset detectable in the peripheral blood of approximately one fourth of healthy subjects. These donors are always serologically positive for human cytomegalovirus. PD-1 is expressed by CD56 but not CD56 NK cells and is confined to fully mature NK cells characterized by the NKG2AKIRCD57 phenotype. Proportions of PD-1 NK cells were higher in the ascites of a cohort of patients with ovarian carcinoma, suggesting their possible induction/expansion in tumor environments. Functional analysis revealed a reduced proliferative capability in response to cytokines, low degranulation, and impaired cytokine production on interaction with tumor targets.
We have identified and characterized a novel subpopulation of human NK cells expressing high levels of PD-1. These cells have the phenotypic characteristics of fully mature NK cells and are increased in patients with ovarian carcinoma. They display low proliferative responses and impaired antitumor activity that can be partially restored by antibody-mediated disruption of PD-1/programmed death ligand interaction.
程序性死亡受体 1(PD-1)是一种免疫检查点,当与肿瘤/病毒感染细胞上表达的特定配体相互作用时,它会向 T 细胞传递强大的抑制信号,从而限制免疫反应,有助于免疫逃逸机制。研究表明,治疗性 PD-1 阻断可介导肿瘤消除,并取得令人瞩目的临床效果。关于 PD-1 在人类自然杀伤(NK)细胞上的表达/功能知之甚少。
我们旨在阐明人类 NK 细胞是否可以表达 PD-1,并分析其表型/功能特征。
我们通过多参数细胞荧光分析,对 PD-1 NK 细胞进行分析,并通过脱颗粒、细胞因子产生和增殖试验对其功能进行了特征分析。
我们提供了确凿的证据表明,PD-1 在大约四分之一的健康供体外周血中可检测到的 NK 细胞亚群上高度表达(PD-1)。这些供体的血清学始终对人类巨细胞病毒呈阳性。PD-1 由 CD56 表达,但不由 CD56 NK 细胞表达,并且局限于具有 NKG2A、KIR、CD57 表型的完全成熟 NK 细胞。卵巢癌患者腹水中 PD-1 NK 细胞的比例较高,提示其可能在肿瘤环境中诱导/扩增。功能分析显示,这些细胞对细胞因子的增殖能力降低,脱颗粒能力低,与肿瘤靶细胞相互作用时细胞因子产生受损。
我们已经鉴定并表征了表达高水平 PD-1 的人类 NK 细胞的新型亚群。这些细胞具有完全成熟 NK 细胞的表型特征,在卵巢癌患者中增加。它们显示出低增殖反应和受损的抗肿瘤活性,通过抗体介导的 PD-1/程序性死亡配体相互作用的破坏可以部分恢复这种活性。